FDA Brief

Warning letters Drugs

FDA warning letter to

Synthetix Inc. DBA Helix Chemical Supply

High riskIssued Feb 7, 2024Posted Feb 13, 2024Center for Drug Evaluation and Research | CDER

FDA says Synthetix Inc., doing business as Helix Chemical Supply, sold unapproved and misbranded Semaglutide and Tirzepatide drugs online.

What happened

FDA reviewed www.helixchem.com in October 2023 and observed that the website offered Semaglutide and Tirzepatide products for sale in the United States. FDA says dose schedules and claims on the site—despite "research use only" and "not for human consumption" statements—show the products are intended as drugs for human use. FDA found no approved applications for the products and says their labeling lacks adequate directions for use, making them unapproved new drugs and misbranded drugs.

What FDA found

  1. FDA says the company offered Semaglutide and Tirzepatide as new drugs without FDA-approved applications.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  2. FDA says the products are misbranded because their labeling does not give adequate directions for use.

    FD&C Act section 502(f)(1), 21 U.S.C. 352(f)(1)
  3. FDA says website dose schedules and claims, including blood sugar, insulin, heart, liver, lung, Alzheimer's, and Mounjaro references, show the products are intended for human use as drugs.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
  4. FDA says the products are prescription drugs because of their toxicity or potential for harmful effects, how they are used, or the supervision needed for use.

    FD&C Act section 503(b)(1)(A), 21 U.S.C. 353(b)(1)(A)
  5. FDA says introducing or delivering misbranded drugs into interstate commerce is prohibited.

    FD&C Act section 301(a), 21 U.S.C. 331(a)

What FDA wants

Respond in writing within 15 working days of receipt of the letter with the specific steps taken to address the violations, how recurrence will be prevented, and related documentation; if corrective actions are not complete, give the reason and planned completion date. Send the response to FDA's Office of Unapproved Drugs and Labeling Compliance by email.

Who should pay attention

  • online sellers of research-use-only peptides
  • clinics or pharmacies buying or offering GLP-1 drugs
  • consumers purchasing semaglutide or tirzepatide online

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk